Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension

Mona Sahlholdt Hansen, Asger Andersen, Sarah Holmboe, Jacob Gammelgaard Schultz, Steffen Ringgaard, Ulf Simonsen, Chris Happé, Harm Jan Bogaard, Jens Erik Nielsen-Kudsk

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: We investigated whether chronic levosimendan treatment can prevent and revert right ventricular (RV) failure and attenuate pulmonary vascular remodeling in a rat model of pulmonary arterial hypertension (PAH). Methods and Results: PAH was induced in rats by exposure to SU5416 and hypoxia (SuHx). The rats were randomized to levosimendan (3 mg·kg -1 ·d -1) initiated before SuHx (n = 10, PREV), levosimendan started 6 weeks after SuHx (n = 12, REV), or vehicle treatment (n = 10, VEH). Healthy control rats received vehicle (n = 10, CONT). Ten weeks after SuHx, RV function was evaluated by echocardiography, magnetic resonance imaging, invasive pressure-volume measurements, histology, and biochemistry. Levosimendan treatment improved cardiac output (VEH vs. PREV 77 ± 7 vs. 137 ± 6 mL/min; P < 0.0001; VEH vs. REV 77 ± 7 vs. 117 ± 10 mL/min; P < 0.01) and decreased RV afterload compared with VEH (VEH vs. PREV 219 ± 33 vs. 132 ± 20 mm Hg/mL; P < 0.05; VEH vs. REV 219 ± 33 vs. 130 ± 11 mm Hg/mL; P < 0.01). In the PREV group, levosimendan restored right ventriculoarterial coupling (VEH vs. PREV 0.9 ± 0.1 vs. 1.8 ± 0.3; P < 0.05) and prevented the development of pulmonary arterial occlusive lesions (VEH vs. PREV 37 ± 7 vs. 15 ± 6% fully occluded lesions; P < 0.05). Conclusion: Chronic treatment with levosimendan prevents and reverts the development of RV failure and attenuates pulmonary vascular remodeling in a rat model of PAH.

Original languageEnglish
Pages (from-to)232-238
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume70
Issue number4
DOIs
Publication statusPublished - 1 Oct 2017

Cite this

Hansen, M. S., Andersen, A., Holmboe, S., Schultz, J. G., Ringgaard, S., Simonsen, U., ... Nielsen-Kudsk, J. E. (2017). Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 70(4), 232-238. https://doi.org/10.1097/FJC.0000000000000508
Hansen, Mona Sahlholdt ; Andersen, Asger ; Holmboe, Sarah ; Schultz, Jacob Gammelgaard ; Ringgaard, Steffen ; Simonsen, Ulf ; Happé, Chris ; Bogaard, Harm Jan ; Nielsen-Kudsk, Jens Erik. / Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension. In: Journal of Cardiovascular Pharmacology. 2017 ; Vol. 70, No. 4. pp. 232-238.
@article{119842a9f742478a9e36480c9fc3a0d9,
title = "Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension",
abstract = "Background: We investigated whether chronic levosimendan treatment can prevent and revert right ventricular (RV) failure and attenuate pulmonary vascular remodeling in a rat model of pulmonary arterial hypertension (PAH). Methods and Results: PAH was induced in rats by exposure to SU5416 and hypoxia (SuHx). The rats were randomized to levosimendan (3 mg·kg -1 ·d -1) initiated before SuHx (n = 10, PREV), levosimendan started 6 weeks after SuHx (n = 12, REV), or vehicle treatment (n = 10, VEH). Healthy control rats received vehicle (n = 10, CONT). Ten weeks after SuHx, RV function was evaluated by echocardiography, magnetic resonance imaging, invasive pressure-volume measurements, histology, and biochemistry. Levosimendan treatment improved cardiac output (VEH vs. PREV 77 ± 7 vs. 137 ± 6 mL/min; P < 0.0001; VEH vs. REV 77 ± 7 vs. 117 ± 10 mL/min; P < 0.01) and decreased RV afterload compared with VEH (VEH vs. PREV 219 ± 33 vs. 132 ± 20 mm Hg/mL; P < 0.05; VEH vs. REV 219 ± 33 vs. 130 ± 11 mm Hg/mL; P < 0.01). In the PREV group, levosimendan restored right ventriculoarterial coupling (VEH vs. PREV 0.9 ± 0.1 vs. 1.8 ± 0.3; P < 0.05) and prevented the development of pulmonary arterial occlusive lesions (VEH vs. PREV 37 ± 7 vs. 15 ± 6{\%} fully occluded lesions; P < 0.05). Conclusion: Chronic treatment with levosimendan prevents and reverts the development of RV failure and attenuates pulmonary vascular remodeling in a rat model of PAH.",
keywords = "heart failure, levosimendan, pulmonary hypertension, right ventricular dysfunction",
author = "Hansen, {Mona Sahlholdt} and Asger Andersen and Sarah Holmboe and Schultz, {Jacob Gammelgaard} and Steffen Ringgaard and Ulf Simonsen and Chris Happ{\'e} and Bogaard, {Harm Jan} and Nielsen-Kudsk, {Jens Erik}",
year = "2017",
month = "10",
day = "1",
doi = "10.1097/FJC.0000000000000508",
language = "English",
volume = "70",
pages = "232--238",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension. / Hansen, Mona Sahlholdt; Andersen, Asger; Holmboe, Sarah; Schultz, Jacob Gammelgaard; Ringgaard, Steffen; Simonsen, Ulf; Happé, Chris; Bogaard, Harm Jan; Nielsen-Kudsk, Jens Erik.

In: Journal of Cardiovascular Pharmacology, Vol. 70, No. 4, 01.10.2017, p. 232-238.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension

AU - Hansen, Mona Sahlholdt

AU - Andersen, Asger

AU - Holmboe, Sarah

AU - Schultz, Jacob Gammelgaard

AU - Ringgaard, Steffen

AU - Simonsen, Ulf

AU - Happé, Chris

AU - Bogaard, Harm Jan

AU - Nielsen-Kudsk, Jens Erik

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: We investigated whether chronic levosimendan treatment can prevent and revert right ventricular (RV) failure and attenuate pulmonary vascular remodeling in a rat model of pulmonary arterial hypertension (PAH). Methods and Results: PAH was induced in rats by exposure to SU5416 and hypoxia (SuHx). The rats were randomized to levosimendan (3 mg·kg -1 ·d -1) initiated before SuHx (n = 10, PREV), levosimendan started 6 weeks after SuHx (n = 12, REV), or vehicle treatment (n = 10, VEH). Healthy control rats received vehicle (n = 10, CONT). Ten weeks after SuHx, RV function was evaluated by echocardiography, magnetic resonance imaging, invasive pressure-volume measurements, histology, and biochemistry. Levosimendan treatment improved cardiac output (VEH vs. PREV 77 ± 7 vs. 137 ± 6 mL/min; P < 0.0001; VEH vs. REV 77 ± 7 vs. 117 ± 10 mL/min; P < 0.01) and decreased RV afterload compared with VEH (VEH vs. PREV 219 ± 33 vs. 132 ± 20 mm Hg/mL; P < 0.05; VEH vs. REV 219 ± 33 vs. 130 ± 11 mm Hg/mL; P < 0.01). In the PREV group, levosimendan restored right ventriculoarterial coupling (VEH vs. PREV 0.9 ± 0.1 vs. 1.8 ± 0.3; P < 0.05) and prevented the development of pulmonary arterial occlusive lesions (VEH vs. PREV 37 ± 7 vs. 15 ± 6% fully occluded lesions; P < 0.05). Conclusion: Chronic treatment with levosimendan prevents and reverts the development of RV failure and attenuates pulmonary vascular remodeling in a rat model of PAH.

AB - Background: We investigated whether chronic levosimendan treatment can prevent and revert right ventricular (RV) failure and attenuate pulmonary vascular remodeling in a rat model of pulmonary arterial hypertension (PAH). Methods and Results: PAH was induced in rats by exposure to SU5416 and hypoxia (SuHx). The rats were randomized to levosimendan (3 mg·kg -1 ·d -1) initiated before SuHx (n = 10, PREV), levosimendan started 6 weeks after SuHx (n = 12, REV), or vehicle treatment (n = 10, VEH). Healthy control rats received vehicle (n = 10, CONT). Ten weeks after SuHx, RV function was evaluated by echocardiography, magnetic resonance imaging, invasive pressure-volume measurements, histology, and biochemistry. Levosimendan treatment improved cardiac output (VEH vs. PREV 77 ± 7 vs. 137 ± 6 mL/min; P < 0.0001; VEH vs. REV 77 ± 7 vs. 117 ± 10 mL/min; P < 0.01) and decreased RV afterload compared with VEH (VEH vs. PREV 219 ± 33 vs. 132 ± 20 mm Hg/mL; P < 0.05; VEH vs. REV 219 ± 33 vs. 130 ± 11 mm Hg/mL; P < 0.01). In the PREV group, levosimendan restored right ventriculoarterial coupling (VEH vs. PREV 0.9 ± 0.1 vs. 1.8 ± 0.3; P < 0.05) and prevented the development of pulmonary arterial occlusive lesions (VEH vs. PREV 37 ± 7 vs. 15 ± 6% fully occluded lesions; P < 0.05). Conclusion: Chronic treatment with levosimendan prevents and reverts the development of RV failure and attenuates pulmonary vascular remodeling in a rat model of PAH.

KW - heart failure

KW - levosimendan

KW - pulmonary hypertension

KW - right ventricular dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85021065951&partnerID=8YFLogxK

U2 - 10.1097/FJC.0000000000000508

DO - 10.1097/FJC.0000000000000508

M3 - Article

VL - 70

SP - 232

EP - 238

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -